Prescient Therapeutics

Prescient Therapeutics Limited (PTX) is a clinical stage oncology company developing novel compounds that show potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy. The company continues to develop its two drug candidates, PTX-100 and PTX-200, for potential new therapies to treat a range of cancers, including breast and ovarian cancer, as well as leukaemia.

Contact Details

Level 4 , 100 Albert Rd SOUTH MELBOURNE VIC 3205

03 9692 7222

www.ptxtherapeutics.com

Lists and Charts

Share price

Prescient Therapeutics
Closing price for the last 90 trading days

View ASX Chart

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
1561^st	Credit Intelligence	-55.9%	-17.39%
1562^nd	Renascor Resources	-56%	38.38%
1563^rd	Prescient Therapeutics	-56%	-14.45%
1564^th	Micro-X	-56.01%	-24.28%
1565^th	Australasian Metals	-56.01%	0%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Company Share Transactions

Company Activity

	NEW ROLE: Gavin Shepherd, Non-Executive Director	07 Aug 2024
	NEW ROLE: Ellen Feigal, Non-Executive Director	07 Aug 2024
	NEWS: Tagged in Where markets meet medicine; a biotech entrepreneur at the tip of the spear	14 Feb 2022
	NEWS: Tagged in Radiopharm scores coup with rare isotope supply deal	01 Feb 2022
	NEW ROLE: Said Sebti, Chief Scientific Officer	24 Nov 2020
	NEW ROLE: Terrence Chew, Chief Medical Officer	24 Nov 2020
	NEW ROLE: Said Sebt,	24 Nov 2020
	NEW ROLE: Allen J Ebens, Non-Executive Director	03 Nov 2020
	NEW ROLE: Melanie Leydin, Company Secretary	03 Nov 2020

News Articles

Monday, 20 January, 2014 - 15:18
Market chemistry grows biotech deals
SPECIAL REPORT: The biotech sector came to life in 2013 but pricing was critical to the success or failure of capital raisings.
Monday, 17 March, 2014 - 15:51
Virax takeover clinches anti-cancer drug
Virax Holdings has agreed to acquire Pathway Oncology in a reverse takeover which will see the Australia-listed company gain control of a global licence for emerging anti-cancer technology.
Tuesday, 25 March, 2014 - 12:10
Virax raises $3m for Pathway takeover
Virax Holdings has completed a $3 million equity placement to sophisticated investors to support its acquisition last week of Pathway Oncology.
Monday, 19 May, 2014 - 13:00
Crombie heads Virax
Biotech company Virax Holdings has appointed Rob Crombie as managing director, from mid-June.Dr Crombie is a scientist with senior management experience at Arana Therapeutics and EvoGenix.He is currently a consultant providing specialist advice to start-up innovation companies.

Virax takeover clinches anti-cancer drug
Monday, 17 March, 2014 - 15:51

Virax raises $3m for Pathway takeover
Tuesday, 25 March, 2014 - 12:10
TimelineJS
Market chemistry grows biotech deals
Virax takeover clinches anti-cancer drug
Virax raises $3m for Pathway takeover
Crombie heads Virax
Aug.
Sept.
Oct.
Nov.
Dec.
Jan.
Feb.
March
April
May
June
July
Aug.
Sept.
Oct.
Nov.
Dec.
Jan.
Feb.
March
April
May
June
July
Aug.
Aug.
Sept.
Oct.
Nov.
Dec.
Jan.
Feb.
March
April
May
June
July
Aug.
Sept.
Oct.
Nov.
Dec.
Jan.
Feb.
March
April
May
June
July
Aug.
Sept.
Oct.
Nov.
Dec.
Jan.
Feb.
March
April
May
June
July
Aug.
Sept.
Oct.
Dec. 21
Dec. 22
Dec. 23
Dec. 24
Dec. 25
Dec. 26
Dec. 27
Dec. 28
Dec. 29
Dec. 30
Dec. 31
Jan. 2
Jan. 3
Jan. 4
Jan. 5
Jan. 6
Jan. 7
Jan. 8
Jan. 9
Jan. 10
Jan. 11
Jan. 12
Jan. 13
Jan. 14
Jan. 15
Jan. 16
Jan. 17
Jan. 18
Jan. 19
Jan. 20
Jan. 21
Jan. 22
Jan. 23
Jan. 24
Jan. 25
Jan. 26
Jan. 27
Jan. 28
Jan. 29
Jan. 30
Jan. 31
Feb. 2
Feb. 3
Feb. 4
Feb. 5
Feb. 6
Feb. 7
Feb. 8
Feb. 9
Feb. 10
Feb. 11
Feb. 12
Feb. 13
Feb. 14
Feb. 15
Feb. 16
Feb. 17
Feb. 18
Feb. 19
Feb. 20
Feb. 21
Feb. 22
Feb. 23
Feb. 24
Feb. 25
Feb. 26
Feb. 27
Feb. 28
March 2
March 3
March 4
March 5
March 6
March 7
March 8
March 9
March 10
March 11
March 12
March 13
March 14
March 15
March 16
March 17
March 18
March 19
March 20
March 21
March 22
March 23
March 24
March 25
March 26
March 27
March 28
March 29
March 30
March 31
April 2
April 3
April 4
April 5
April 6
April 7
April 8
April 9
April 10
April 11
April 12
April 13
April 14
April 15
April 16
April 17
April 18
April 19
April 20
April 21
April 22
April 23
April 24
April 25
April 26
April 27
April 28
April 29
April 30
May 2
May 3
May 4
May 5
May 6
May 7
May 8
May 9
May 10
May 11
May 12
May 13
May 14
May 15
May 16
May 17
May 18
May 19
May 20
May 21
May 22
May 23
May 24
May 25
May 26
May 27
May 28
May 29
May 30
May 31
June 2
June 3
June 4
June 5
June 6
June 7
June 8
June 9
June 10
June 11
June 12
June 13
June 14
June 15
June 16
June 17

Related Information

Access to our data for Prescient Therapeutics is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Prescient Therapeutics is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today

Prescient Therapeutics

Contact Details

Lists and Charts

Share price

Share price

Total Shareholder Return as at 02/12/24

Total Shareholder Return as at 02/12/24

Company Share Transactions

Company Share Transactions

Company Activity

Monday, 20 January, 2014 - 15:18

Market chemistry grows biotech deals

Monday, 17 March, 2014 - 15:51

Virax takeover clinches anti-cancer drug

Tuesday, 25 March, 2014 - 12:10

Virax raises $3m for Pathway takeover

Monday, 19 May, 2014 - 13:00

Crombie heads Virax

Market chemistry grows biotech deals

Virax takeover clinches anti-cancer drug

Virax raises $3m for Pathway takeover

Crombie heads Virax

Related Information